<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003513</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066556</org_study_id>
    <secondary_id>BC-NB-2</secondary_id>
    <nct_id>NCT00003513</nct_id>
  </id_info>
  <brief_title>Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma</brief_title>
  <official_title>Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burzynski Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Burzynski Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current therapies for Metastatic, Recurrent, or Refractory Neuroblastoma provide very limited&#xD;
      benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it&#xD;
      may prove beneficial in the treatment of Metastatic, Recurrent, or Refractory Neuroblastoma.&#xD;
&#xD;
      PURPOSE: This study is being performed to determine the effects (good and bad) that&#xD;
      Antineoplaston therapy has on patients with Metastatic, Recurrent, or Refractory&#xD;
      Neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic, Recurrent, or Refractory Neuroblastoma patients receive gradually escalating&#xD;
      doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum&#xD;
      tolerated dose is reached. Treatment continues up to12 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the efficacy of Antineoplaston therapy in patients with Metastatic,&#xD;
           Recurrent, or Refractory Neuroblastoma, as measured by an objective response to therapy&#xD;
           (complete response, partial response or stable disease).&#xD;
&#xD;
        -  To determine the safety and tolerance of Antineoplaston therapy in patients with&#xD;
           Metastatic, Recurrent, or Refractory Neuroblastoma.&#xD;
&#xD;
        -  To determine objective response, tumor size is measured utilizing MRI scans, which are&#xD;
           performed every 8 weeks for the first two years, every 3 months for the third and fourth&#xD;
           years, every 6 months for the 5th and sixth years, and annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">December 16, 1996</start_date>
  <completion_date type="Actual">March 29, 1999</completion_date>
  <primary_completion_date type="Actual">March 29, 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Antineoplaston therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antineoplaston therapy (Atengenal + Astugenal)</intervention_name>
    <description>Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).&#xD;
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.</description>
    <arm_group_label>Antineoplaston therapy</arm_group_label>
    <other_name>A10 (Atengenal); AS2-1 (Astugenal)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed incurable neuroblastoma that is unlikely to respond to&#xD;
             existing therapy, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Progressive, recurrent, or persistent disease after initial therapy, including&#xD;
                  surgery, chemotherapy, and/or radiotherapy&#xD;
&#xD;
          -  Measurable disease by MRI or CT scan&#xD;
&#xD;
          -  Tumor must be at least 2 cm&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  6 months and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No hepatic insufficiency&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No renal insufficiency&#xD;
&#xD;
          -  Creatinine no greater than 2.5 mg/dL&#xD;
&#xD;
          -  No history of renal conditions that contraindicate high dosages of sodium&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No history of other cardiovascular conditions that contraindicate high dosages of&#xD;
             sodium&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No serious lung disease, such as chronic obstructive pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No nonmalignant systemic disease&#xD;
&#xD;
          -  Not a high medical or psychiatric risk&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 8 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior cytodifferentiating agents allowed&#xD;
&#xD;
          -  No prior antineoplastons&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanislaw R. Burzynski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Burzynski Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burzynski Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055-6330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.burzynskiresearch.com</url>
    <description>Burzynski Research Institute</description>
  </link>
  <link>
    <url>http://www.burzynskiclinic.com</url>
    <description>Burzynski Clinic</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Neuroblastoma</keyword>
  <keyword>Recurrent Neuroblastoma</keyword>
  <keyword>Refractory Neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

